Target intelligence / Profile preview

Gut microbiome–host intestinal interface (null)

Target: null
Molecular classification: Other

Overview

The gut microbiome–host intestinal interface is the functional and physical zone where trillions of microorganisms (the gut microbiota) interact with the host’s intestinal epithelium and immune system. This interface consists of the mucus and epithelial barrier, antimicrobial peptides, immune cells, and the dense microbial community, and is essential for maintaining host health through regulation of metabolism, immune homeostasis, and protection against pathogens. Disruption of this interface can lead to increased gut permeability, immune dysregulation, and is implicated in a range of diseases including infections, inflammatory disorders, metabolic syndrome, cancer, and neuropsychiatric conditions.

Other names: Gut microbiota–host interfaceMicrobiome–intestinal barrierIntestinal mucosal interfaceGut–host crosstalk

Mechanism of action

Alteration of microbial composition (dysbiosis restoration); Enhancement of gut barrier function; Modulation of microbial metabolite production (e.g., SCFAs, indoles); Immune modulation (promotion of Treg cells, suppression of pro-inflammatory cytokines).

Biological functions

Maintenance of gut barrier integrityRegulation of host immune responseMetabolic exchange (production and absorption of microbial metabolites)Protection against pathogensHost–microbe signaling and crosstalk (including neuroendocrine and immune signaling)Modulation of inflammation and immune tolerance

Disease associations

Inflammatory diseases (e.g., inflammatory bowel disease, allergy, autoimmune conditions)Infection (altered barrier allows pathogen translocation)Metabolic disorders (e.g., obesity, diabetes)Neuropsychiatric disorders (via gut–brain axis alterations)Cancer (colorectal and possibly others)

Safety considerations

Off-target effects of drugs on the wider microbiome (antibiotic resistance, unintended dysbiosis)Translocation of pathogens or pathobionts across a compromised barrier (bacteremia/sepsis)Unpredictable immune effects (autoimmunity, allergy exacerbation)Long-term ecological shifts in the microbiome may have downstream health risks

Interacting drugs

Probiotics (e.g., Lactobacillus, Bifidobacterium)

5 more in the full profile.

Biomarkers

Fecal microbial diversity (16S rRNA or metagenomic sequencing profile)Fecal/serum levels of short-chain fatty acids (butyrate, acetate, propionate)Markers of gut permeability (zonulin, LPS-binding protein)Proportions of specific microbial taxa (e.g., ratio of Firmicutes to Bacteroidetes)

Beyond the preview

Go deeper on Gut microbiome–host intestinal interface (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiome–host intestinal interface (null).

Explore the full profile